Autopsy report · NCT03559387

Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia

“Study redesign”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months after it had already started.
• Ran for about 10 months before it stopped.
• 9 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Prolong Pharmaceuticals

Sponsor type

Industry

Conditions

Chemotherapy-induced Neutropenia

Interventions

ANF-RHO™; Neulasta®

Participants

9

Sites

8

Countries

France, Netherlands

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.